Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14494696 | 0.91 | L3MBTL1 (0.49) | L3MBTL1CFDHTR6BRD4PTGDR2 | |
| SCHEMBL1718083 | 0.90 | L3MBTL1 (0.48) | L3MBTL1CFDHTR6BRD4PTGDR2 | |
| SCHEMBL12346589 | 0.87 | L3MBTL1 (0.54) | L3MBTL1HTR6BRD4PIK3C3RAPGEF4 | |
| SCHEMBL1779961 | 0.86 | L3MBTL1 (0.57) | L3MBTL1HTR6BRD4PTGDR2RAPGEF4 | |
| SCHEMBL14494698 | 0.84 | L3MBTL1 (0.48) | L3MBTL1HTR6BRD4PTGDR2PIK3C3 | |
| SCHEMBL10125557 | 0.84 | L3MBTL1 (0.48) | L3MBTL1CFDHTR6PTGDR2PIK3C3 | |
| SCHEMBL10125556 | 0.83 | PRKCI (0.47) | L3MBTL1CFDHTR6MAP2K4BRD4 | |
| SCHEMBL1781229 | 0.82 | L3MBTL1 (0.56) | L3MBTL1BRD4PTGDR2RAPGEF4PKM | |
| SCHEMBL1718127 | 0.82 | JMJD6 (0.45) | L3MBTL1PIK3C3 | |
| SCHEMBL2237896 | 0.81 | L3MBTL1 (0.62) | L3MBTL1HTR6BRD4PTGDR2RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1881983-A1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | Vertex Pharmaceuticals, Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| WO-2006127587-A1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | L3MBTL1 3383/4885CFD 4786/4885HTR6 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.